Immunotherapy with interleukin-2 by constant infusion with and without adoptive cell transfer and with weekly doxorubicin

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

Steven A. Rosenberg, Michael T. Lotze, Linda Muul et al. · New England Journal of Medicine · 1987 · 2.8K citations

Pharmacy, Immunology, Oncology +14

Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

Steven A. Rosenberg, Michael T. Lotze, Linda Muul et al. · New England Journal of Medicine · 1985 · 2.6K citations

Medicine, Immunology, Oncology +15

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Elizabeth A. Grimm, A Mazumder, H Z Zhang et al. · The Journal of Experimental Medicine · 1982 · 2.2K citations · Full text

Life Sciences, Immunology, Oncology +15

Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer

William H. West, Kurt W. Tauer, John R. Yannelli et al. · New England Journal of Medicine · 1987 · 1.2K citations

Medicine, Immunology, Oncology +16

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

Michael T. Lotze, Yvedt L. Matory, Stephen E. Ettinghausen et al. · The Journal of Immunology · 1985 · 614 citations

Life Sciences, Immunology, Pharmacology +9